New drug combo aims to slow advanced lung cancer

This study tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy and chest radiation can help people with extensive-stage small cell lung cancer live longer without their cancer growing. About 46 adults aged 18-75 who have not had prior treatment for this cancer will take part. The main goal is to see how long it takes for the cancer to progress.